That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
dc.contributor.author | Davis, Matthew R. | |
dc.contributor.author | McCreary, Erin K. | |
dc.contributor.author | Pogue, Jason M. | |
dc.date.accessioned | 2022-08-10T18:46:00Z | |
dc.date.available | 2022-08-10T18:46:00Z | |
dc.date.issued | 2020-07-10 | |
dc.identifier.uri | https://doi.org/10.1007/s40121-020-00318-1 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/173966 | en |
dc.description.abstract | Abstract Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020. | |
dc.title | That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19 | |
dc.type | Journal Article | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173966/1/40121_2020_Article_318.pdf | |
dc.identifier.doi | https://dx.doi.org/10.7302/5697 | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s) | |
dc.date.updated | 2022-08-10T18:45:59Z | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.